Design Therapeutics (DSGN)
Nasdaq Market Closed
Design Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for serious genetic diseases linked to nucleotide repeat expansions. These disorders are caused by abnormal repeated DNA sequences that can disrupt gene expression or lead to toxic RNA and protein effects. The company’s work is centered on its GeneTAC platform, which is designed to create small-molecule gene targeted chimera candidates that act at the genetic source of disease rather than only treating symptoms.
The company’s lead areas of research include Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type 1, and Huntington’s disease. Each of these conditions has a significant genetic component and limited treatment options, making them a focus for disease-modifying drug development. Design Therapeutics seeks to design compounds that selectively interact with disease-associated repeat sequences and modulate the underlying biology in a precise and potentially durable way.
As a clinical-stage company, Design Therapeutics does not operate like a diversified commercial pharmaceutical business. Its value is tied primarily to the progress of its research programs, the safety and efficacy data generated in clinical studies, and the strength of its proprietary technology platform. The company operates as a single reportable segment focused on discovering and developing GeneTAC therapeutic candidates. For investors, DSGN represents exposure to an early-stage drug development model in rare and inherited diseases, where successful clinical validation could be meaningful but development risk remains high.
Last updated
- Market Cap
- 635.19M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 622.42M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 6005 HIDDEN VALLEY ROAD, CARLSBAD, CA, 92011
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
Nvidia climbs, D.R. Horton gets a Buffett boost, and other stocks on the move
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 635.19M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 622.42M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.91
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -7.97
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -1.12
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -54.12M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -31.97%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -30.25%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 22.28
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 22.28
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.25
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.11M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 10.17
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -19.71M | -18.17M | -19.31M | -21.57M | -20.42M |
| EBITDA | -19.55M | -18.01M | -19.16M | -21.42M | -20.26M |
| Net income | -17.64M | -16M | -17M | -19.08M | -17.72M |
| Basic EPS | -0.29 | -0.27 | -0.3 | -0.34 | -0.31 |
| Diluted EPS | -0.29 | -0.27 | -0.3 | -0.34 | -0.31 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 230.44M | 226.2M | 211.77M | 222.89M | 237.48M |
| Total liabilities | 12.39M | 13.7M | 12.05M | 9.85M | 9.56M |
| Total equity | 218.05M | 212.5M | 199.72M | 213.04M | 227.92M |
| Cash & equivalents | 12.77M | 16.86M | 15.09M | 19.7M | 13.67M |
| Current assets | 227.05M | 223.78M | 209.03M | 219.79M | 233.64M |
| Current liabilities | 10.19M | 13.06M | 11.17M | 8.75M | 8.24M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -16.43M | -11.97M | -11.16M | -14.44M | -16.79M |
| Investing cash flow | -7.59M | -11.58M | 6.51M | 20.12M | 7.87M |
| Financing cash flow | 19.93M | 25.32M | 37K | 361K | 23K |
| Change in cash | -4.09M | 1.77M | -4.62M | 6.04M | -8.9M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Design Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Design Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Design Therapeutics, Inc. | View Filing | |
| edgar index | 10-Q — Design Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | ARS — Design Therapeutics, Inc. | View Filing | |
| edgar index | DEF 14A — Design Therapeutics, Inc. | View Filing | |
| edgar index | DEFA14A — Design Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Design Therapeutics, Inc. | View Filing | |
| edgar index | 3 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Shapiro David | View Filing | |
| form 4 | Form 4 — Shapiro David | View Filing | |
| edgar index | SCHEDULE 13D/A — Design Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Design Therapeutics, Inc. | View Filing | |
| edgar index | 10-K — Design Therapeutics, Inc. | View Filing | |
| edgar index | S-8 — Design Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13G/A — Design Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Design Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Shah Pratik | View Filing | |
| form 4 | Form 4 — Storgard Chris | View Filing | |
| form 4 | Form 4 — Gover Justin D. | View Filing | |
| form 4 | Form 4 — Jeffries Sean | View Filing | |
| form 4 | Form 4 — Burgess Julie | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Shah Pratik | View Filing | |
| edgar index | SCHEDULE 13D/A — Design Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Design Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Design Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Design Therapeutics, Inc. | View Filing | |
| edgar index | 10-Q — Design Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Design Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Gover Justin D. | View Filing | |
| form 4 | Form 4 — Gover Justin D. | View Filing | |
| edgar index | SCHEDULE 13G — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Design Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — William Arsani | View Filing | |
| form 4 | Form 4 — William Arsani | View Filing | |
| edgar index | 8-K — Design Therapeutics, Inc. | View Filing | |
| edgar index | 10-Q — Design Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Design Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — George Simeon | View Filing | |
| form 4 | Form 4 — LAPPE RODNEY W | View Filing | |
| form 4 | Form 4 — Berger Heather A. | View Filing | |
| form 4 | Form 4 — Prasad Deepa | View Filing | |
| form 4 | Form 4 — Schmid John P. | View Filing | |
| form 4 | Form 4 — William Arsani | View Filing |